Obesity and the Lymphatic System: A Two-Way Street Reshaping Metabolic Disease Research

For decades, the lymphatic system has been treated as the quiet understudy of the circulatory network, remembered mainly for draining fluid and ferrying immune cells. A new review published in the International Journal of Obesity argues that this view has badly undersold the network of vessels that threads through nearly every tissue in the body. Led by Yitong Hao, Yutong Zhang and colleagues at Tianjin University of Traditional Chinese Medicine, the analysis synthesizes evidence that the lymphatic system is deeply entangled in lipid metabolism, inflammation control and immune regulation, and that its dysfunction may be both a consequence and a driver of obesity. The central claim is provocative: obesity and lymphatic failure reinforce each other in a bidirectional loop, and breaking that loop could open entirely new avenues for prevention and treatment.

The scale of the problem the review addresses is hard to overstate. Obesity has become a global public health crisis, and according to the World Obesity Federation’s 2025 atlas its continued rise poses significant risks for cardiovascular disease, type 2 diabetes and several cancers, while reducing life expectancy. Traditional explanations have centered on energy balance, adipose tissue expansion and chronic low-grade inflammation. What has been missing, the authors contend, is a systematic account of how the lymphatic vasculature participates in this pathology. Their review, published on 25 September 2026, sets out to map the mechanisms of interaction between lymphatic dysfunction and obesity, and to ask which direction the causality runs, a question that remains only partially answered.

Understanding the argument requires appreciating how unusual lymphatic vessels are at the structural level. Unlike blood vessels, collecting lymphatics are lined by endothelial cells joined by specialized button-like junctions that act as flaps, allowing fluid, proteins and immune cells to enter freely while preventing backflow. In the intestine, these vessels form lacteals, blind-ended capillaries in each villus that absorb dietary fat packaged into chylomicrons. The junctions between lacteal endothelial cells are remarkably plastic: work cited in the review showed that zippering these junctions shut in mice protects against diet-induced obesity by limiting fat uptake, while fibroblast subsets in the villi regulate lacteal integrity through YAP/TAZ-driven production of vascular endothelial growth factor C, or VEGF-C. In other words, the architecture of the lymphatic drainage system directly tunes how many calories the gut absorbs.

The molecular machinery governing lymphatic identity and function is equally central to the story. The transcription factor Prox1 induces the lymphatic endothelial phenotype, working with COUP-TFII to specify cell fate, while the VEGF-C/VEGFR-3 signaling axis drives lymphangiogenesis, the growth of new lymphatic vessels. VEGFR-3 signaling is required for button junction formation, and ligand-induced heterodimerization with VEGFR-2 shapes phosphorylation patterns in lymphatic endothelial cells. Other players refine the network further: semaphorin 3A, neuropilin-1 and plexin-A1 are needed for lymphatic valve formation, FOXC2 and fluid shear stress stabilize vessels after birth, and eNOS controls valve specification through beta-catenin signaling. When any of these pathways falter, the consequences ripple outward, because lymphatics do far more than drain fluid. They mediate macrophage reverse cholesterol transport, remove cholesterol from peripheral tissues via SR-BI-mediated HDL transport, and serve as gatekeepers that shape immune tolerance through molecules such as PD-L1.

Against this backdrop, the evidence that obesity damages lymphatics is strikingly consistent. Mouse studies have shown that obesity impairs lymphatic fluid transport and dendritic cell migration to lymph nodes, and that chronic high-fat feeding degrades collecting vessel function even before gross metabolic disease appears. Hypercholesterolemic mice exhibit lymphatic vessel dysfunction and degeneration, and ApoE-deficient animals show multiple facets of lymphatic failure, including valve dysfunction on western diets. In obese animals, mesenteric lymph nodes display increased fibrosis and altered immune cellularity, and obesity-associated lymph leakage impairs the trafficking of lipids, lipophilic drugs and antigens from the intestine. Mechanistically, inflammatory cytokines appear to be key culprits: tumor necrosis factor alpha inhibits lymphatic pumping through the NF-kappaB and inducible nitric oxide synthase pathway, and inflammatory mediators disrupt endothelial barrier function. Obesity, in this framing, is an environment in which lymphatic vessels progressively choke.

Crucially, the review emphasizes that the damage is not merely collateral. Lymphatic insufficiency feeds back into metabolic disease. Mesenteric lymphatic dysfunction has been shown to promote insulin resistance, positioning the lymphatic system as a potential treatment target rather than a passive victim. Deletion of the fatty acid transporter CD36 specifically in lymphatic endothelial cells associates with visceral obesity and insulin resistance, while RAMP1 signaling deletion enhances diet-induced obesity and fat absorption through intestinal lacteals. In Prox1-haploinsufficient mice, which have inherently compromised lymphatics, restoring lymphatic function rescued the obese phenotype, one of the most direct demonstrations that lymphatic failure can cause obesity rather than simply accompany it. Lymphatic vessel insufficiency in hypercholesterolemic mice also alters lipoprotein levels and promotes atherosclerosis, extending the loop to cardiovascular disease.

The immune dimension adds another layer of complexity. Adipose tissue in obesity accumulates macrophages, and a paracrine loop between adipocytes and macrophages, driven by free fatty acids and tumor necrosis factor alpha, aggravates inflammation. Adipokines modulate this crosstalk: leptin, elevated in obesity, compromises lymphatic endothelial cell homeostasis by impairing tube formation and proliferation, and leptin-VEGF crosstalk has been implicated in excess body mass and related disorders. Adiponectin, by contrast, protects the system, modulating lymphatic vessel formation and reducing lymphedema. T lymphocytes negatively regulate lymph node lymphatic vessel formation, Th2 cytokines inhibit lymphangiogenesis, and transforming growth factor beta 1 blockade accelerates lymphatic regeneration during wound repair. Specialized pro-resolving mediators such as lipoxins interact with the lymphatic system to resolve inflammation, suggesting that the vessels are active participants in the inflammatory arc of obesity, from ignition to resolution.

What makes the review timely is its treatment implications. The authors highlight that obesity-induced lymphatic dysfunction is reversible with weight loss, and that exercise training improves obesity-related lymphatic dysfunction in animal models. A lymphoscintigraphic study found that lower extremity lymphatic function can be predicted by body mass index, linking clinical imaging to the mechanistic work. Inhibition of inflammation and inducible nitric oxide synthase improves lymphatic function in obesity, and a case report described semaglutide treatment in a patient with extreme obesity and massive lymphedema, hinting that the new generation of metabolic drugs may act partly through lymphatic pathways. Manual lymphatic drainage has been shown to alter adipokine and cytokine concentrations and markers of insulin resistance in patients with abnormal body mass index, while electroacupuncture combined with intradermal needling has been reported to influence serum markers of intestinal lymphatic function in simple obesity. Even GLP-2 has been shown to stimulate lacteal contractility and enhance chylomicron transport when the enteric nervous system is intact.

The therapeutic frontier the review sketches is correspondingly broad. Pharmacological modulation of the VEGF-C/VEGFR-3 axis could either promote lymphatic growth where vessels have failed or, in the intestinal context, be tuned to limit fat absorption, since blockade of VEGF-C and VEGF-D has been shown to modulate adipose tissue inflammation and improve metabolic parameters under high-fat diet conditions. Apelin, which inhibits diet-induced obesity by enhancing lymphatic and blood vessel integrity, represents another candidate pathway, as do receptors such as GPR182, recently identified as a lipoprotein receptor for dietary fat absorption, and the ERAD machinery protein AIDA, which selectively downregulates fat synthesis enzymes to retard intestinal fat uptake and prevent obesity. Targeting lymphatic muscle cells, valve function and junctional zippering each offer distinct intervention points, though the authors are careful to note that the directionality of causality between lymphatic dysfunction and obesity is not yet fully resolved, and that much of the evidence remains preclinical.

The broader significance of the work lies in reframing. If the lymphatic system sits at the junction of fat absorption, cholesterol trafficking, immune signaling and inflammation resolution, then it is not a peripheral curiosity in metabolic disease but a potential control node. The review, funded by the National Natural Science Foundation of China, systematically assembles the case that protecting or restoring lymphatic function could complement diet, exercise and incretin-based therapies, and that lymphatic biomarkers might one day identify patients at risk of obesity-driven metabolic complications before they manifest. It also raises an urgent clinical question: with obesity-linked lymphedema rising alongside waistlines worldwide, understanding the bidirectional crosstalk between fat and lymph may prove essential to treating both. The vessels that drain our tissues, long overlooked, may hold one of the keys to the obesity epidemic.

Subject of Research: Bidirectional relationship between lymphatic dysfunction and obesity in metabolic disease pathogenesis and therapy

Article Title: Bidirectional crosstalk between obesity and the lymphatic system: a novel pathway in obesity pathogenesis and treatment

Article References: Hao, Y., Zhang, Y., Zong, J., Wu, G., Wang, Y., Wang, J., & Wang, Y. (2026). Bidirectional crosstalk between obesity and the lymphatic system: a novel pathway in obesity pathogenesis and treatment. International Journal of Obesity. https://doi.org/10.1038/s41366-026-02178-0

Image Credits: AI Generated

DOI: 10.1038/s41366-026-02178-0

Keywords: obesity, lymphatic system, lymphatic dysfunction, VEGF-C, lacteals, lipid metabolism, inflammation, insulin resistance, lymphangiogenesis, adipokines, metabolic disease, lymphedema